160 related articles for article (PubMed ID: 24891362)
1. VEGFA genomic amplification tailors treatment of HCCs with sorafenib.
Luo X; Feng GS
Cancer Discov; 2014 Jun; 4(6):640-1. PubMed ID: 24891362
[TBL] [Abstract][Full Text] [Related]
2. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
3. Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Llovet JM
Cancer Cell; 2014 May; 25(5):560-2. PubMed ID: 24823635
[TBL] [Abstract][Full Text] [Related]
4. Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
Gores GJ
Nat Rev Gastroenterol Hepatol; 2014 Nov; 11(11):645-7. PubMed ID: 25245016
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of hepatocellular carcinoma with sorafenib.
Rombolà F; Spinoso A
Infez Med; 2013 Jun; 21(2):167-8. PubMed ID: 23774984
[No Abstract] [Full Text] [Related]
6. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
7. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
8. Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Shin SK; Jung YK; Yoon HH; Kwon OS; Kim YS; Choi DJ; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):47-50. PubMed ID: 24463289
[TBL] [Abstract][Full Text] [Related]
9. Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
Sacco R; Bargellini I; Ginanni B; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Tumino E; Di Biase M; Bresci G; Bartolozzi C
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S89-92. PubMed ID: 21975578
[No Abstract] [Full Text] [Related]
10. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Tanoglu A; Karagoz E
Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
[No Abstract] [Full Text] [Related]
11. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Berasain C
Gut; 2013 Dec; 62(12):1674-5. PubMed ID: 23481262
[No Abstract] [Full Text] [Related]
12. Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
Lulla PD; Brammer JE; Bandeali S; Lynch GR
J Gastrointest Cancer; 2013 Mar; 44(1):98-101. PubMed ID: 23054578
[No Abstract] [Full Text] [Related]
13. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
16. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
Piscaglia F; Salvatore V; Venerandi L
Dig Liver Dis; 2013 May; 45(5):367-8. PubMed ID: 23562444
[No Abstract] [Full Text] [Related]
17. Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Azmi AN; Chan WK; Goh KL
J Dig Dis; 2015 Sep; 16(9):537-40. PubMed ID: 26147446
[No Abstract] [Full Text] [Related]
18. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
de Stefano G; Iodice V; Farella N
J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
[No Abstract] [Full Text] [Related]
19. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
Shao YY; Hsu CH; Cheng AL
World J Gastroenterol; 2015 Sep; 21(36):10336-47. PubMed ID: 26420960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
